Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide

Ipsen (Euronext: IPN; ADR: IPSEY) and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227). IPN01087 is a compound that targets cancer cells in...

More

Eckert & Ziegler Q3/2018: Increase in Revenue in all Business Segments

Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, increased the earnings per share to €2.50 in the third quarter of 2018 and thus reached...

More

NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC

NOXXON ends the use of variable rate equity financing with Yorkville

More

TU Berlin: In focus: Peptides, the “little brothers and sisters” of proteins

A new Research Training Group aims to decode the complex structure of peptides. The German Research Foundation is to provide EUR 4.5 million in funding for the research

More

Revolutionizing the production of novel diagnostics with cost-effective Roll-to-Roll imprinting

R2R Biofluidics EU project recently received the Austrian Fast Forward Award 2018

More

OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation

Proceeds provide OMEICOS with the financial runway to conduct the Phase II Study PROMISE-AF and continue expansion into ophthalmology through US subsidiary

More

ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks

 

ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded...

More

Forbion Leads €17m Series C Financing of OMEICOS Therapeutics

 

Forbion invests €12.5m from its recently launched Forbion IV fund

OMEICOS is pioneering the development of stable analogs of omega-3 fatty acid metabolites for Cardiovascular Disease and Ophthalmology

Forbion, a leading European life science...

More

Intelligent glove wins World Health Summit Startup Award 2018

Eyeluminati from India chosen out of 60 applications from 19 countries

More

“Together we are strong!”

10th World Health Summit has kicked off in Berlin/Germany

More
Show more items